ADIPONRF2

Targeting the Keap1/Nrf2 pathway in adipose tissue for obesity prevention and treatment

Coordinatore	UNIVERSITY OF PATRAS    more  Organization address address: UNIVERSITY CAMPUS RIO PATRAS city: RIO PATRAS postcode: 26500 contact info Titolo: Dr. Nome: Ioannis Cognome: Habeos Email: send email Telefono: 302611000000
Nazionalità Coordinatore	Greece [EL]
Totale costo	252˙742 €
EC contributo	252˙742 €
Programma	FP7-PEOPLE Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	FP7-PEOPLE-2012-IOF
Funding Scheme	MC-IOF
Anno di inizio	2013
Periodo (anno-mese-giorno)	2013-05-01   -   2016-04-30

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UNIVERSITY OF PATRAS  Organization address address: UNIVERSITY CAMPUS RIO PATRAS city: RIO PATRAS postcode: 26500 contact info Titolo: Dr. Nome: Ioannis Cognome: Habeos Email: send email Telefono: 302611000000	EL (RIO PATRAS)	coordinator	252˙742.20

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'This research addresses the question of how the manipulation of Keap1/Nrf2 signaling in adipose tissue affects the development of obesity and metabolic syndrome. Nrf2 is a central orchestrator of a battery of antioxidant and cytoprotective genes in response to oxidative or electrophilic stress and there is growing evidence that it cross-talks with other pathways. Our previous works showed that the whole body deletion of Nrf2 protected, at least partially, mice from high-fat diet (HFD)-induced obesity and insulin resistance and led to impaired adipogenesis. Another study has shown that mice treated with an Nrf2 activator, the triterpenoid CDDO-Im, were also protected from HFD-induced obesity. However, little is known about the exact mechanisms involved and which tissue is the main contributor to the resulting phenotype. Taking into account that there is in vitro evidence that Nrf2 is implicated in adipogenesis by crosstalking with transcription factors central to the adipocyte differentiation (PPARgamma, C/EBP beta), the main focus of this research will be to develop a murine model with conditional deletion of Nrf2 (loss of Nrf2 function) or Keap1 (gain of Nrf2 function) in adipose tissue using the Cre-recombinase-loxP system. Using both these models we will study how genetic manipulation of Nrf2 specifically in adipose tissue affects the development of HFD-induced obesity, the oxygen and energy consumption, the insulin resistance and the expression of genes involved in adipogenesis and lipid metabolism in adipose and other tissues in the different genotypes. Experiments using primary adipocyte cultures will give a mechanistic insight into adipogenesis and insulin signaling. This work will advance the field of obesity by actually being the first work that scrutinously characterize Nrf2 as a novel target for obesity prevention and treatment and possibly pave the way for relevant future clinical trials using Keap1/Nrf2 pathway modifying agents.'